NASDAQ:XLO | Free Cash Flow | Xilio Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$22.34M$556,000.00-$22.9M
2025-12-31-$2M$95,000.00-$2.09M-20.20%
2025-03-31$28.98M$22,000.00$28.96M
2024-12-31-$14.16M$6,000.00-$14.16M
2024-03-31-$10.5M
2023-12-31-$13.43M$0.00-$13.43M
2023-03-31-$25.25M$170,000.00-$25.42M
2022-12-31-$18.22M$509,000.00-$18.73M
2022-03-31-$20.84M$254,000.00-$21.09M
2021-12-31-$17.16M$378,000.00-$17.54M
2021-03-31-$22.73M$170,000.00-$22.9M
2020-12-31-$12.71M$108,000.00-$12.81M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$4.99M$518,000.00-$5.51M
2024-12-31-$18.38M$36,000.00-$18.41M
2023-12-31-$68.62M$486,000.00-$69.11M
2022-12-31-$75.72M$1.87M-$77.59M
2021-12-31-$80.75M$1.1M-$81.85M
2020-12-31-$36.09M$2.19M-$38.28M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.